
---
nice.evidencecategory: 
---

### Evidence Statement CG66ES69
Reports of adverse effects were higher in the acarbose groups across all studies.99,101106 The
main difference between the treatment groups was the high frequency of GI complaints
reported by acarbose-treated patients. Flatulence was reported in all acarbose arms ranging
from 28.6% to 57.5% of all patien

[@Gray_2000]

[@Unkown_date]

[@Rosenthal_2002]

[@Rosenthal_2002]

[@Rosenthal_2002]

[@Rosenthal_2002]

[@Rosenthal_2002]

[@Rosenthal_2002]

[@Rosenthal_2002]

